CN Patent
CN110917159A — 阿片样物质受体调节剂剂型
Assigned to Erjian Holding Co Ltd · Expires 2020-03-27 · 6y expired
What this patent protects
本发明涉及阿片样物质受体调节剂剂型,具体涉及含有5‑({[2‑氨基‑3‑(4‑氨基甲酰基‑2,6‑二甲基‑苯基)‑丙酰基]‑[1‑(4‑苯基‑1H‑咪唑‑2‑基)‑乙基]‑氨基}‑甲基)‑2‑甲氧基‑苯甲酸的滥用戒除剂固体剂型,和用于制备和施用这些制剂的方法。
USPTO Abstract
本发明涉及阿片样物质受体调节剂剂型,具体涉及含有5‑({[2‑氨基‑3‑(4‑氨基甲酰基‑2,6‑二甲基‑苯基)‑丙酰基]‑[1‑(4‑苯基‑1H‑咪唑‑2‑基)‑乙基]‑氨基}‑甲基)‑2‑甲氧基‑苯甲酸的滥用戒除剂固体剂型,和用于制备和施用这些制剂的方法。
Drugs covered by this patent
- Viberzi (ELUXADOLINE) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.